Investigational drug · Phase 2
SYH2072
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Uncontrolled Hypertension, Resistant Hypertension, Primary Aldosteronism.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "SYH2072"
First trial start
2026
Nov 13, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYH2072", any sponsor or status.
Conditions studied
As listed on its trial records.
- Uncontrolled Hypertension
- Resistant Hypertension
- Primary Aldosteronism
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SYH2072" as an intervention, largest first.
- A Study Evaluating the Efficacy and Safety of SYH2072 Tablets In Hypertensive PatientsPivotal-lookingNot yet recruiting
InnovStone Therapeutics LimitedIndustry
NCT07911735 · 264 participants (planned) · Start Dec 13, 2026 · Primary completion Jul 22, 2027
Drug: SYH2072 Tablets; SYH2072 Tablets and 2 more · For: Uncontrolled Hypertension; Resistant Hypertension
- A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 TabletsPivotal-lookingRecruiting
InnovStone Therapeutics LimitedIndustry
NCT07647783 · 112 participants (planned) · Start Jan 15, 2026 · Primary completion Feb 1, 2027
Drug: SYH2072 Tablets; SYH2072 Placebo · For: Healthy Participants
Sites: Beijing, China
- SYH2072 Tablets in Participants With Primary AldosteronismNot yet recruiting
InnovStone Therapeutics LimitedIndustry
NCT07917039 · 60 participants (planned) · Start Nov 13, 2026 · Primary completion Feb 1, 2028
Drug: SYH2072 tablets; Placebo · For: Primary Aldosteronism
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Uncontrolled Hypertension
- SAL0120Phase 32 trials
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Chronic Kidney Disease, Uncontrolled Hypertension, Resistant Hypertension
- SAL0140Phase 23 trials
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Primary Aldosteronism, Chronic Kidney Disease, Uncontrolled Hypertension
- of QLS1410Phase 22 trials
Qilu Pharmaceutical Co., Ltd. · Hypertension (HTN), Uncontrolled Hypertension
- RTN-001SLx-2101Phase 21 trial
Retension Pharmaceuticals. Inc. · Uncontrolled Hypertension
- VB19055Phase 21 trial
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · Hypertension, Resistant Hypertension, Uncontrolled Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.